TELA Bio opened lower at $0.93, compared with its previous close of $0.94. In the last trading session, the stock traded between $0.79 and $1.03. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in TELA Bio is now worth
$ 6.81
Resulting in a loss of
$ 93.19 (93.19%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
75%
Hold
25%
Sell
0%
Markets Today
Today's Change
$-0.10 (-10.17%)
Day High
$1.03
Day Low
$0.79
Day Open
$0.93
Prev Close
$0.94
Volume
1,90,787
1W Return
-3.09%
1M Return
-23.72%
3M Return
6.95%
6M Return
-12.79%
1Y Return
-28.91%
Fundamentals
Market Cap ($ Mn)
38
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-305.11%
ROCE
-57.87%
EPS (TTM)
$-0.25
Investment Returns
1 Week
-3.09%
1 Month
-23.72%
3 Months
6.95%
6 Months
-12.79%
9 Months
2.62%
Financials
Quarterly
All values in $ Mn
18.5
Mar 25
20.2
Jun 25
20.7
Sep 25
20.9
Dec 25
19.1
Mar 26
19.3
Jun 26
Updates
11Nov
Tela Bio Q3FY26 results: Revenue falls 8% YoY to $19 million
Revenue fell 8% YoY to $19 million in Q3FY26. Adjusted EBITDA loss narrowed 40% YoY to $3.4 million. European revenue grew 18% YoY, offsetting U.S. declines. Gross margin contracted to 64.9% due to inventory charges.
2 days ago
7Nov
TELA Bio grants 108,550 RSUs to new hires under Nasdaq rule
TELA Bio granted restricted stock units covering 108,550 shares to four new employees. Grants were issued under Nasdaq Rule 5635(c)(4) inducement exception. 58,550 shares vest annually over four years; 50,000 shares vest after one year. Grant date for the awards was November 4, 2026.
6 days ago
31Aug
TELA Bio cuts $17M in costs, extends cash runway to 2028
TELA Bio targets $17.0 million in annual operating expense reductions. Workforce streamlining includes a 20% targeted headcount reduction. One-time restructuring charge of $1.5 million expected in Q3 2026. Cash runway extended into 2028 following cost-cutting measures. Roberto Cuca steps down as COO and CFO effective immediately.
2mo ago
11Aug
TELA Bio misses Q2 revenue, withdraws full-year guidance
TELA Bio's Q2 2026 results showed a 4% YoY revenue decline to $19.3 million and a widened net loss of $11.3 million, missing analyst expectations. Gross margin improved to 72% due to tariff refunds, but operating expenses remained flat. New CEO Heather Getz withdrew full-year guidance, citing the need to address PRS volume declines and pricing headwinds while focusing on cost discipline and market share gains in hernia repairs.
3mo ago
21Jul
TELA Bio to announce second quarter 2026 financial results on August 10
TELA Bio, Inc. will release its second quarter 2026 financial results on August 10, 2026, followed by a conference call at 4:30 p.m. ET. The company focuses on soft-tissue reconstruction solutions, aiming to optimize clinical outcomes through innovative technologies.
